Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASMB Assembly Biosciences	$18.84 +0.5%	$15.74	$7.75 ▼ $19.93	$143.90M	0.62	27,883 shs	13,726 shs
ATOS Atossa Genetics	$0.94 -0.2%	$0.86	$0.55 ▼ $1.66	$120.98M	0.9	757,859 shs	662,307 shs
CRBP Corbus Pharmaceuticals	$8.36 +1.1%	$7.81	$4.64 ▼ $61.90	$102.33M	3.05	337,952 shs	87,180 shs
ENOB Enochian Biosciences		$0.61	$0.39 ▼ $2.99	$40.80M	1.09	137,347 shs	88,300 shs
INFI Infinity Pharmaceuticals		$0.07	$0.01 ▼ $0.01	$726K	1.63	2.58 million shs	2.48 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASMB Assembly Biosciences	0.00%	+3.31%	+11.28%	+83.82%	+26.69%
ATOS Atossa Genetics	0.00%	+13.48%	+13.00%	+48.97%	-28.36%
CRBP Corbus Pharmaceuticals	0.00%	+8.70%	-6.34%	+42.59%	-85.96%
ENOB Enochian Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%
INFI Infinity Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASMB Assembly Biosciences	3.7143 of 5 stars	3.3	3.0	0.0	4.7	2.3	0.0	0.0
ATOS Atossa Genetics	3.183 of 5 stars	3.7	4.0	0.0	0.0	3.8	1.7	0.0
CRBP Corbus Pharmaceuticals	4.4784 of 5 stars	3.6	3.0	0.0	4.7	2.6	2.5	0.6
ENOB Enochian Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
INFI Infinity Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASMB Assembly Biosciences	2.67	Moderate Buy	$33.00	75.16% Upside
ATOS Atossa Genetics	3.33	Buy	$6.17	558.41% Upside
CRBP Corbus Pharmaceuticals	3.10	Buy	$50.88	508.55% Upside
ENOB Enochian Biosciences	0.00	N/A	N/A	N/A
INFI Infinity Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest INFI, CRBP, ASMB, ENOB, and ATOS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/6/2025	ATOS Atossa Genetics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.25 ➝ $7.50
6/5/2025	ATOS Atossa Genetics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$4.00
5/7/2025	CRBP Corbus Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/7/2025	CRBP Corbus Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$65.00 ➝ $58.00
5/7/2025	CRBP Corbus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$60.00 ➝ $56.00
5/7/2025	CRBP Corbus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $40.00
4/21/2025	ATOS Atossa Genetics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $7.25

(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASMB Assembly Biosciences	$32.15M	4.48	N/A	N/A	$5.25 per share	3.59
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	$0.57 per share	N/A
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	$11.69 per share	N/A
ENOB Enochian Biosciences	N/A	N/A	N/A	N/A	$1.37 per share	N/A
INFI Infinity Pharmaceuticals	$2.59M	0.00	N/A	N/A	($0.21) per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASMB Assembly Biosciences	-$40.18M	-$6.23	N/A	N/A	N/A	-124.15%	-131.77%	-36.81%	8/6/2025 (Estimated)
ATOS Atossa Genetics	-$25.50M	-$0.21	N/A	N/A	N/A	N/A	-33.90%	-31.53%	8/11/2025 (Estimated)
CRBP Corbus Pharmaceuticals	-$40.21M	-$4.22	N/A	N/A	N/A	N/A	-36.87%	-32.87%	8/5/2025 (Estimated)
ENOB Enochian Biosciences	-$113.43M	N/A	0.00	N/A	N/A	N/A	-154.69%	-130.66%	N/A
INFI Infinity Pharmaceuticals	-$44.37M	-$0.46	N/A	N/A	N/A	-1,593.93%	N/A	-113.02%	N/A

Latest INFI, CRBP, ASMB, ENOB, and ATOS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	ATOS Atossa Genetics	-$0.06	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	CRBP Corbus Pharmaceuticals	-$1.35	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	ATOS Atossa Genetics	-$0.06	-$0.05	+$0.01	-$0.05	N/A	N/A
5/8/2025	Q1 2025	ASMB Assembly Biosciences	-$2.01	-$1.17	+$0.84	-$1.17	$7.41 million	$9.42 million
5/6/2025	Q1 2025	CRBP Corbus Pharmaceuticals	-$1.26	-$1.39	-$0.13	-$1.39	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASMB Assembly Biosciences	N/A	N/A	N/A	N/A	N/A
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	N/A
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ENOB Enochian Biosciences	N/A	N/A	N/A	N/A	N/A
INFI Infinity Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASMB Assembly Biosciences	N/A	2.05	2.05
ATOS Atossa Genetics	N/A	12.67	12.67
CRBP Corbus Pharmaceuticals	N/A	11.82	11.82
ENOB Enochian Biosciences	N/A	0.33	0.33
INFI Infinity Pharmaceuticals	N/A	1.65	1.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASMB Assembly Biosciences	19.92%
ATOS Atossa Genetics	12.74%
CRBP Corbus Pharmaceuticals	64.64%
ENOB Enochian Biosciences	7.16%
INFI Infinity Pharmaceuticals	22.14%

Insider Ownership

Company	Insider Ownership
ASMB Assembly Biosciences	5.30%
ATOS Atossa Genetics	8.70%
CRBP Corbus Pharmaceuticals	4.00%
ENOB Enochian Biosciences	21.72%
INFI Infinity Pharmaceuticals	9.81%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASMB Assembly Biosciences	100	7.64 million	7.25 million	Optionable
ATOS Atossa Genetics	8	129.17 million	117.93 million	Optionable
CRBP Corbus Pharmaceuticals	40	12.24 million	11.75 million	Optionable
ENOB Enochian Biosciences	22	58.28 million	45.63 million	Not Optionable
INFI Infinity Pharmaceuticals	30	90.76 million	81.86 million	Optionable

INFI, CRBP, ASMB, ENOB, and ATOS Headlines

Recent News About These Companies

Renal Cell Carcinoma Pipeline Appears Robust With 30+ Companies Actively Working in the Therapeutics Segment | DelveInsight

May 7, 2025 | theglobeandmail.com

BMS and Infinity aim to overcome triple negative breast cancer resistance to IO

February 24, 2025 | pharmaphorum.comP

S-Infinity Pharmaceuticals patents new MAP3K8 kinase inhibitors

January 3, 2025 | bioworld.comB

Infinity Nikki release date, launch times, trailers, and latest news

November 15, 2024 | pcgamesn.comP

Infinity Mining secures Bogong Copper-Gold Project in Australia

November 6, 2024 | mining-technology.comM

Memphis nightclub shot up, shattering window but no injuries found, police say

October 25, 2024 | fox13memphis.comF

Multibagger Pharma Stock To Keep Under Radar As Board Likely To Announce Stock Split

October 20, 2024 | dsij.inD

Anavo Therapeutics Appoints Dr. Edward Holson as Chief Scientific Officer and President US

October 9, 2024 | dutchnews.nlD

Thinking of Trying Collagen? What to Know About the Benefits and Drawbacks

September 29, 2024 | msn.com

Bajaj Healthcare enters into development and supply agreement for API with European entity

September 24, 2024 | financialexpress.comF

Govt boosts incentives for tech upgrade by pharma units

September 24, 2024 | financialexpress.comF

Gradiant Announces ProtiumSource, the World's Most Complete Electrolyzer-Ready Water Solution, Tailored to the Needs of Green Hydrogen Producers

September 24, 2024 | en.antaranews.comE

Particle Size Analysis Market Size to Reach US$ 816.10 Million by 2032 With an Emerging CAGR of 5.88% | Report by SNS Insider

September 20, 2024 | finance.yahoo.com

Triple Negative Breast Cancer Clinical Trials, Treatment Drugs, Pipeline Insights, and Companies 2024

September 20, 2024 | theglobeandmail.com

JAGSONPAL PHARMACEUTICALS LTD. - Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011

September 18, 2024 | money.rediff.comM

Collagen Supplements: What They Can Do for Your Body and What to Watch For

September 18, 2024 | msn.com

Collagen Supplements: Benefits, Drawbacks and How to Add It to Your Diet

August 30, 2024 | msn.com

Woman shot while driving in South Memphis

August 20, 2024 | msn.com

Young player Memphis just traded attends Ja Morant's party

August 16, 2024 | msn.com

High Court orders issue of notice to Karnataka govt. on petition to transfer Valmiki scam case to CBI

July 23, 2024 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INFI, CRBP, ASMB, ENOB, and ATOS Company Descriptions

Assembly Biosciences NASDAQ:ASMB

$18.84 +0.09 (+0.48%)

Closing price 04:00 PM Eastern

Extended Trading

$18.77 -0.07 (-0.37%)

As of 05:44 PM Eastern

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Atossa Genetics NASDAQ:ATOS

$0.94 0.00 (-0.20%)

Closing price 04:00 PM Eastern

Extended Trading

$0.92 -0.01 (-1.45%)

As of 07:59 PM Eastern

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Corbus Pharmaceuticals NASDAQ:CRBP

$8.36 +0.09 (+1.09%)

Closing price 04:00 PM Eastern

Extended Trading

$8.35 -0.01 (-0.17%)

As of 07:50 PM Eastern

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Enochian Biosciences NASDAQ:ENOB

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer. The company's product pipeline includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a gene therapy curative treatment for HBV. It develops ENOB-DC-11, an allogeneic dendritic cell therapeutic vaccine for solid tumors; ENOB-DC-12-XX, allogeneic dendritic cell therapeutic vaccine for other solid tumors; and ENOB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. Enochian Biosciences, Inc. has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was incorporated in 2017 and is headquartered in Los Angeles, California.

Infinity Pharmaceuticals NASDAQ:INFI

Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time